It’s no surprise that cancer remains an urgent healthcare priority around the world. What may be surprising for some to learn is how the disease particularly impacts people of color. While cancer deaths among Black people, for example, have declined, this group still experiences the highest cancer death rates of any population group. They’re also less likely to get diagnosed and treated for the leading causes of cancer deaths, such as lung cancer.
One critical way to reduce cancer health disparities is to make clinical trials more representative of patients. That’s why Johnson & Johnson is collaborating with partners to build and promote the advancement of Diversity, Equity and Inclusion (DEI) in clinical trials and reduce the many barriers preventing equitable trials from happening.
For World Health Day, we’re taking a look at cancer inequities across the globe and the role Johnson & Johnson is playing.
